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Abstract 
 Generalised anxiety disorder (GAD) is a common, chronic and debilitating mental disorder 
impairing quality of life and functioning. The 1st line treatments for GAD include the 
selective serotonergic reuptake inhibitors (SSRIs) and the selective serotonergic 
noradrenergic reuptake inhibitors (SNRIs). However, they have rates of non-response 
ranging from 25 to 40%. There is justification to search for new and more efficacious GAD 
medication. It has hypothesised anticonvulsants possess anxiolytic properties based on 
animal studies and epilepsy trials. There is inconsistent evidence that anticonvulsants are 
efficacious in GAD. It was considered useful and timely to investigate this further. The 
newer anticonvulsants (felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, 
pregabalin, tiagabine, topiramate and zonisamide) were investigated as they were considered 
to have a more benign side effect profile and fewer drug interactions than older 
anticonvulsants. 
 This study is a systematic review and meta-analysis of the newer anticonvulsants in the 
treatment of GAD. The main objective was to use randomised controlled trial (RCT) data to 
estimate efficacy of the newer anticonvulsants in GAD. using A search strategy was 
designed and three separate searches conducted by the Cochrane Depression Anxiety and 
Neurosis Group of the Cochrane Collaboration Depression, Anxiety and Neurosis 
Controlled Trials Register (CCDANCTR) and clinicaltrials.gov (the last search in May 
2013). An updated, independent, search was conducted in May 2016 with no additional 
citations retrieved. 287 citations were retrieved and screened in total. Two independent 
raters assessed citations using the abstracts and selected trials that satisfied the inclusion 
criteria. 12 RCTs were included with eight using pregabalin and four using tiagabine. A 
single rater collated data from RCTs assisted by Covidence Systematic Review Software. 
All statistical analyses were performed using Review Manager. 
 A random effects meta-analysis was performed expressing summary statistics as effect 
estimates with 95% confidence intervals (CI). There were 4001 participants in total with 
2516 in the anticonvulsant group and 1485 in the placebo. Primary outcomes were reduction 
in symptom severity using the Hamilton Anxiety Rating Scale (HAM-A) and treatment 
response using the Clinical Global Impressions Scale-Improvement item (CGI-I). Secondary 
outcome was medication acceptability. Reduction of symptom severity on the HAM-A for: 
the anticonvulsant group (pregabalin and tiagabine combined) was significantly favourable 
with a mean difference (MD) of -2.10 ([-2.83, -1.36] 95% CI); pregabalin was significantly 
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favourable (MD -2.86 [-3.52, -2.21] 95% CI) tiagabine was statistically insignificant (MD -
0.58 [-1.41, 0.25] 95% CI). The risk ratio (RR) of treatment response using the CGI-I (RR 
>1 favours the anticonvulsant) for: the anticonvulsant group was significantly favourable
(RR 1.23 [1.12, 1.35] 95% CI); pregabalin was significantly favourable (RR 1.35 [1.21,
1.50] 95% CI) tiagabine was statistically insignificant (RR 1.09 [0.98, 1.22] 95% CI). The
RR of treatment acceptability (RR >1 favoured placebo) for: the anticonvulsant group was
significantly unfavourable (RR 1.49 [1.18, 1.88] 95% CI); pregabalin was statistically
insignificant (RR 1.23 [0.92, 1.65] 95% CI) tiagabine was significantly unfavourable (RR
1.95 [1.29, 2.93] 95% CI).
In conclusion, this systematic review of the newer anticonvulsants included only RCTs of 
pregabalin and tiagabine. The main finding was that pregabalin showed significant efficacy 
in reducing symptom severity and improving treatment response in GAD. Tiagabine failed 
to show significant efficacy in primary outcomes. Further work is needed to better clarify 
the place of the newer anticonvulsants in the treatment armamentarium of GAD. 
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Chapter 1 
Introduction and Background 
Generalised anxiety disorder (GAD) is a debilitating mental disorder primarily characterised 
by excessive worry along with troublesome somatic strain, tension and personal distress 
(Allgulander, 2006; 2012). GAD has a high degree of morbidity, decreases quality of life, 
and results in poor social and occupational functioning. It tends to run a chronic course 
throughout life, with frequent relapses, and has a high degree of psychiatric co-morbidity 
(Allgulander, 2012; Angst, Gamma, Baldwin, et al., 2009; Allgulander, 2006; Hoffman, 
Dukes & Wittchen, 2008). 
 GAD is common worldwide, with recent surveys of the general population in various parts 
of the world suggesting a lifetime prevalence of 4.3-5.9% and a 12-month prevalence of 
approximately 1-2% (Baldwin, Waldman & Allgulander, 2011)(Kessler et al. 2001) The 
prevalence rate of GAD in South Africa is thought to be similar to overseas rates based on 
data from a local study(Stein, Seedat, Herman, et al., 2008).GAD has been found to be the 
most common anxiety disorder encountered in the primary care setting (Wittchen, Kessler, 
Beesdo, et al., 2002). In addition, GAD is also considered the most common anxiety 
disorder in older age groups (Lieb, Becker & Altamura, 2005).  
The level of disability associated with GAD is comparable to that of a long-term physical 
illness such as asthma or diabetes (Maier, Gänsicke, Freyberger, et al., 2009). Hence, GAD 
can lead to significant increases in the utilisation of health services, increase health care 
expenditure and, therefore, add to the financial strain placed on an economy (Kessler, Keller 
& Wittchen, 2001; Stein, Seedat, Herman, et al., 2008). 
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The Rational for the Investigation of Other Psychotropics in the Treatment 
of GAD  
 
The recommended 1st line treatments for GAD include predominantly the SSRI’s and 
SNRI’s (Bandelow, Sher, Bunevicius, et al., 2012; Baldwin, Anderson, Nutt, et al., 2005). 
However, they are estimated to have high rates of non-response in the region of 25 to 40% 
(Baldwin, Waldman & Allgulander, 2011). Among the tricyclic antidepressants there is 
good evidence to support the use of imipramine in GAD (Bandelow, Boerner J, Kasper, et 
al., 2013). Although effective, the tricyclic antidepressants carry troublesome anticholinergic 
side effects and can be fatal in overdose (Bandelow, Boerner J, Kasper, et al., 2013). 
Numerous studies have found the 5-HT1A agonist, buspirone, effective in treating GAD  
(Bandelow, Boerner J, Kasper, et al., 2013). However, there is conflicting evidence where it 
is was found inferior to venlafaxine and one controlled unsuccessful trial (Bandelow, 
Boerner J, Kasper, et al., 2013). The antihistamine, hydroxyzine, showed some efficacy in a 
small number of controlled trials, however,  it never established itself as a recognised 
treatment option (Bandelow, Boerner J, Kasper, et al., 2013). Benzodiazepines are extremely 
efficacious in the short term treatment of GAD (Gould, Otto, Pollack, et al., 1997). 
However, their long term use is severely hampered by their potential for abuse, development 
of dependence and the high risk associated with a medically unsupervised withdrawal 
(Mula, 2011). There is some evidence supporting the use of the atypical antipsychotics in 
GAD, particularly quetiapine, but also including adjunctive use of risperidone and 
olanzapine in treatment refractory cases (Kreys & Phan, 2015; Samuel, Zimovetz, Gabriel, 
et al., 2011). However, the metabolic and potential extrapyramidal side effects of 
antipsychotics, like tardive dyskinesia, remain a problem (Kreys & Phan, 2015). There 
appears to be no evidence to support the use of beta-blockers such as propranolol in GAD 
(Steenen, van Wijk, van der Heijden, et al., 2016). Despite all the above treatment options, 
the majority of patients with GAD still fail to achieve remission. Hence, there is a need to 
continue searching other avenues for new, more effective and safer medications in the 
treatment of GAD.   
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The Rational for Investigating the Newer Anticonvulsants as Interventions 
in GAD 
 
In this review the newer anticonvulsants are defined as those brought to market from 1985 
onwards which includes felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, 
pregabalin, tiagabine, topiramate and zonisamide. It is hypothesised that these agents may 
possess anxiolytic properties. This suggestion is based on observations from their use in 
clinical trials for other indications as well some early data from animal studies. In addition, 
the currently postulated mechanisms as to how these agents might work, forms a theoretical 
basis for explaining how they might act as anxiolytics.  
 
There is evidence from animal studies which supports the anxiolytic properties of some of 
the newer anticonvulsants (Lamberty, Falter, Gower, et al., 2003; Mirza, Bright, Stanhope, 
et al., 2005). There is supporting evidence from epilepsy trials in which patients displayed 
improved mood and reduced anxiety after treatment with various newer anticonvulsants 
(Smith, Chadwick, Baker, et al., 1993) . There is some evidence to suggest that the newer 
anticonvulsants may be more benign and have a lower side effect burden (Besag, 2001). 
There is preliminary evidence that suggests that the newer anticonvulsants may pose less 
risks of drug-drug interactions compared to older agents (French, Kanner, Bautista, et al., 
2004; LaRoche & Helmers, 2004). 
 
Although the precise mechanism of action of how an anticonvulsant may produce anxiolysis 
is not fully clear, various hypotheses exist. It is known from research in epilepsy that 
sensitisation and “kindling of neurons occur when repeated stimuli of the same neurons 
leads to a decrease in their firing threshold (Post, 2007). The link of the ictal “kindling” 
phenomenon to mood disorders has been frequently suggested in the past. It is possible that 
such a mechanism may also underlie the formation of abnormal neuronal firing  in the 
circuits posited to be involved in anxiety disorders (Post, 2007). 
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 Hence, the reduction in “kindling” by anticonvulsants could result in reduced firing of the 
abnormal neuronal circuits implicated in GAD and thereby result in anxiolysis. This would 
specifically involve reducing excessive neuronal activity in several key areas and circuits 
including: the amygdala; the hippocampus and the cortico-striatal-thalamo-cortical (CSTC) 
circuits (Post, 2007; Grunze, 2008; Stahl, 2004a). The “kindling” process is thought to 
primarily involve excessive activity of the excitatory neurotransmitter glutamate and 
decreased activity of the inhibitory neurotransmitter 𝛾-aminobutyric acid (GABA) (Ashton 
& Young, 2003). Anticonvulsants are thought to lead to a reduction in glutamatergic activity 
and an increase in GABAergic activity (Ashton & Young, 2003). In keeping with this, there 
is evidence suggesting anticonvulsant therapy demonstrates side effects that are in 
accordance with raised GABAergic and decreased glutamatergic activity (Ketter, Post & 
Theodore, 1999).  
 
Anticonvulsants are complicated molecules with the majority having multiple mechanisms 
of action. Still, the current evidence supports the hypothesis that anticonvulsants produce 
anxiolysis primarily by increasing GABAergic activity and regulating voltage-sensitive 
calcium channels (VSCC’s) (Aroniadou-Anderjaska, Qashu & Braga, 2006; Goddard, 
Narayan, Woods, et al., 1996). Conversely, although barbiturates, vigabatrin, tiagabine and 
topiramate, for instance, can be considered GABAergic compounds, this property alone does 
not ensure they will all act as anxiolytics (Mula, 2011). It is possible that this is due to the 
complexity of the circuits and various receptor subtypes that comprise the GABAergic 
system (Mula, 2011). Additionally, the varied and complex mechanisms of action of 
anticonvulsants make predicting their potential side effects difficult. For example, the four 
GABAergic compounds mentioned above, particularly topiramate, happen to be associated 
with significant cognitive impairment, but this side effect is not associated with all 
GABAergic anticonvulsants (Mula & Trimble, 2009).  
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The mechanism of modulating neuronal VSCC’s seems to be highly efficacious in reduction 
of anxiety symptoms (Stahl, 2004a; Mula, 2011). This mechanism of action is not a new 
development as a number of existing anticonvulsants are thought to block VSCC’s to some 
extent in addition to having other effects (Mula, 2011). However, there are particular 
anticonvulsants that are thought to act only via the modulation of the N and P/Q subtypes of 
VSCC’s. These particular calcium channels, which are located presynaptically, are critical 
for the regulation of neurotransmitter release. More precisely, it is the the α2δ subunits, of 
the N and P/Q calcium channels, which are thought to play a critical role in the 
pathophysiology of anxiety (Stahl, 2004a). α2δ subunits, when opened by a current, allow an 
influx of calcium molecules into the nerve terminal, leading to the release of glutamate into 
the synapse via excitation-secretion coupling. It is hypothesised that through modulation of 
α2δ subunits, excessive glutamatergic activity in abnormal circuits in GAD can be 
dampened, while still allowing normal levels of glutamate neurotransmission to occur once 
the situation is stabilised (Stahl, 2004a). 
 
Gabapentin and pregabalin are known as α2δ ligands. They are believed to bind to open N 
and P/Q calcium channels that are firing excessively and causing elevated glutamatergic 
activity (Stahl, 2004b). These agents are thought to modulate these calcium channels by 
binding to the α2δ subunits, reducing the influx of calcium into the cell, thereby normalising 
excessive glutamatergic activity, and theoretically producing anxiolysis (Stahl, 2004a; Mula, 
2011). Once the aberrant neurocircuitry in GAD is stabilised, the α2δ ligands are believed to 
maintain a physiological level of glutamatergic activity through ongoing regulation of the 
stabilised VSCC’s (Stahl, 2004b). 
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The Importance and Utility of This Review 
 
For many reasons, a systematic review of the efficacy of anticonvulsants in GAD is useful at 
this time, as the last such reviews of these agents in anxiety disorders were many years ago 
(Mula, 2011; Pande, Pollack, Crockatt, et al., 2007; Kinrys & Wygant, 2005; Van 
Ameringen, Mancini, Pipe, et al., 2004a). The  review conducted by Mula (2011) noted that 
in many instances the evidence base was thin, consisting mostly of case reports and open 
label studies with few randomised controlled trials. The review highlighted that there were 
problems associated with the existing trials. Some were methodologically unsound in that 
they lacked sufficient sample size, utilised different assessment scales, lacked a placebo 
control or did not account for comorbidities (Mula, 2011). As a result there were 
inconsistent findings regarding the efficacy of anticonvulsants in GAD. Overall, Mula 
(2011) felt that the study of anticonvulsants in anxiety disorders including GAD warranted 
further investigation.  
 
It is hoped that the evidence base has matured since the last reviews were undertaken and 
that higher quality data may be available. With this in mind, it could be valuable to obtain a 
more recent reflection of the usefulness of the newer anticonvulsants in GAD. Conducting a 
methodologically rigorous systematic review and meta-analysis investigating the efficacy 
and acceptability of these agents in GAD should provide such information.  
 
Objectives: Purpose of this study 
 
A) Use RCT data to evaluate the net effects of the newer anticonvulsants in enhancing 
treatment response and reducing symptom severity in GAD.  
 B) To establish whether the efficacy and acceptability of specific anticonvulsants are 










Felbamate received approval from the Food and Drug Administration (FDA), for the 
treatment for epilepsy, first among the the newer anticonvulsants considered in this review 
(LaRoche & Helmers, 2004). The mechanism of action of felbamate is thought to based on 
the modulation of both sodium and calcium voltage-sensitive channels leading to inhibition 
of glutamatergic activity and, to a lesser extent, potentiation of GABAergic activity (Mula, 
2011). Unfortunately, felbamate is associated with significant risks of both hepatotoxicity 
and development of aplastic anaemia (Borowicz, Piskorska, Kimber-Trojnar, et al., 2004). 
This has curtailed its use in epilepsy and possibly investigation into its use in other 
disorders. No evidence was found regarding the use of felbamate in other psychiatric 




As discussed above, gabapentin is an α2δ ligand which binds to N and P/Q VSCC’s located 
on the presynaptic neuronal membrane. Through this action, it is thought to regulate the 
influx of calcium into cells and thereby prevent excessive glutamatergic activity in 
neurocircuits related to anxiety. Some promising evidence is known to exist for gabapentin’s 
efficacy in other anxiety disorders such as social anxiety disorder, panic disorder and 
posttraumatic stress disorder (PTSD) (Urbano, Spiegel, Laguerta, et al., 2009; Pollack, 





The structure of the lamotrigine molecule is unlike other anticonvulsants (Ipser & Stein, 
2006). The mechanism of action of lamotrigine is thought to include the modulation of 
voltage-sensitive sodium channels (VSSC’s), the modulation of VSCC’s, glutamatergic 
inhibition and GABAergic potentiation (Mula, 2011; Stahl, 2013). It has already proved to 
be successful, in a number of RCT’s and reviews, in the treatment of mood disorders  
(Boylan, Devinsky, Barry, et al., 2002). Even in other anxiety disorders, data is mainly 
limited to small open label studies and case reports. However, its showed some promising 
data, from a small RCT in the treatment of PTSD (Hertzberg, Butterfield, Feldman, et al., 
1999). Unfortunately, lamotrigine is associated with a small, but significant, risk of 
developing Steven-Johnsons syndrome of about 1%. It is estimated that Steven-Johnsons 
syndrome can lead to mortality rates of between 5% to 15% (Ghislain & Roujeau, 2002; 




Levetiracetam is known to bind with strong affinity to the synaptic vesicle protein known as 
SV2A and thereby modulate the process of exocytosis of neurotransmitters (Stahl, 2013). It 
is also postulated to reduce the action of negative modulators of GABA-gated and glycine-
gated channels as well as have some effects on N type calcium channels (Stahl, 2013). On 
the basis of its mechanism of action, it is thought that levetiracetam may possess anxiolytic 
properties. There is some, generally poor quality, data of its use in anxiety disorders. There 
is data, although conflicting, on its effectiveness in SAD (Stein, Ravindran, Simon, et al., 
2010; Zhang, Connor & Davidson, 2005; Simon, Worthington, Doyle, et al., 2004). There 
was some positive data in using levetiracetam in treatment resistant PTSD (Kinrys, Wygant, 





Oxcarbazepine is not a metabolite but rather the 10-keto analogue of carbamazepine (Stahl, 
2013). Its mechanism of action involves binding to and modulating VSSC’s, some binding 
and modulation of VSSC’s and producing some degree of glutamatergic inhibition (Mula, 
2011; Stahl, 2013). Unlike carbamazepine, oxcarbazepine does not seem to be associated 
with leukopenia, aplastic anaemia, hepatotoxicity and dangerous skin rashes and seems to 
have fewer drug-drug interactions (Stahl, 2013). Its most significant risk is hyponatraemia 
which can occur in up to 3% of patients (Stahl, 2013). There are some case reports and 
anecdotal evidence that suggest oxcarbazepine has potential efficacy in PTSD and panic 





Pregabalin is an α2δ ligand which binds to N and P/Q VSCC’s on presynaptic membranes 
and thereby modulates calcium influx and glutamatergic neurotransmission. It shares this 
mechanism of action with gabapentin but its effect appears to be more potent (Stahl, 2013). 
Evidence seems to suggest its side effect profile is comparatively mild compared to the other 
newer anticonvulsants. Its side effects are mainly limited to sedation, dizziness and a 
moderate degree of weight gain (Stahl, 2013). It is useful that pregabalin has few, if any, 
pharmacokinetic drug interactions as it is excreted, unchanged, renally, and does not 
undergo hepatic metabolism (Stahl, 2013). There already existed, in 2011, an evidence base 
supporting the efficacy of pregabalin in treating GAD (Mula, 2011). However, the data on 
pregabalin has continued to grow since then. Pregabalin is officially approved for the 
treatment of GAD in Europe, however, does not yet have FDA approval in the United States. 
It has shown efficacy in treating chronic pain and is approved by the FDA for the treatment 
of fibromyalgia syndrome (Sommer, Häuser, Alten, et al., 2012). It appears to show efficacy 
in other anxiety disorders such SAD, has been investigated as an adjunct in treating major 
depressive disorder (MDD) and to facilitate the withdrawal process of benzodiazepine 
dependent patients (Feltner, Pollack, Davidson, et al., 2000; Vitali, Tedeschini, Mistretta, et 





Topiramate is thought to act via multiple mechanisms including the modulation of VSSC’s 
and VSCC’s, acting as a carbonic anhydrase inhibitor and enhancing  GABAergic as well as 
reducing glutamatergic activity (Stahl, 2006). Topiramate has significant side effects 
limiting its use. It can cause troublesome sedation and is thought to produce cognitive 
impairment generally more severe compared to other anticonvulsants. It can potentially 
result in a metabolic acidosis and has been associated with the development of kidney stones 
(Stahl, 2006; Brunbech & Sabers, 2002). There is some early but conflicting evidence for its 
use in PTSD, SAD and obsessive compulsive disorder (OCD) (Berlant, 2000; 2004; Van 
Ameringen, Mancini, Pipe, et al., 2004b; Rubio, Jimenez-Arriero, Martinez-Gras, et al., 
2006). Topiramate use can potentially lead to significant weight loss. This has resulted in the 
off-label use of topiramate as a weight-loss agent, with some clinicians prescribing it to 





Tiagabine is believed to work via selectively blocking the reuptake of GABA by transporters 
at the presynaptic region of neurons and on glial cells (Stahl, 2006). It is thought to primarily 
potentiate the GABAergic system and not affect any other neurotransmitters systems or ion 
channels directly (Mula, 2011). Tiagabine may have troublesome side effects including 
sedation, cognitive impairment and the development of new onset seizures in patients 
without epilepsy (Stahl, 2014). It is also thought to potentially pose a long-term 
ophthalmological risk through its binding to melanin (Stahl, 2006). Tiagabine is mainly 
metabolised by the hepatic cytochrome enzyme CYP450 3A4. The induction or inhibition of 
this enzyme by other drugs makes tiagabine susceptible to significant fluctuations in its 
plasma level. Frequently used psychotropics including many of the mood-stabilising 
anticonvulsants and common antidepressants can alter CYP450 3A4 activity (Stahl, 2006). 
Tiagabine had received earlier attention regarding its potential efficacy in GAD supported 
by an early, but growing evidence base (Mula, 2011). The evidence at that time was limited 
to a few RCTs, open label studies and case series (Kinrys & Wygant, 2005). There is small 
body of evidence of the use of tiagabine in other anxiety disorders, including PTSD and 
SAD, but is mostly limited to open label studies and case series (Crane, 2003; Zwanzger, 
Eser, Nothdurfter, et al., 2009; Taylor, 2003; Dunlop, Papp, Garlow, et al., 2007; Kinrys & 




The mechanism of action of vigabatrin is thought to occur via the inhibition of GABA 
transaminase leading to an increase in the total amount of GABA in the brain (Zwanzger & 
Rupprecht, 2005). Vigabatrin is not a benign medication with visual field abnormalities 
occurring in up to 33% of patients (Kalviainen, Nousiainen, Mantyjarvi, et al., 1999). There 
seems to be some low-level evidence suggesting its possible efficacy in panic disorder 





Zonisamide can be structurally classified as a sulfonamide (Leppik, 2004). Many details 
remain unknown regarding the mechanism of action of zonisamide. It is thought to modulate 
VSSC’s via an unknown mechanism (Stahl, 2014).T-type VSCC’s, which perform a 
function that is currently unclear, are believed to be modulated by zonisamide (Stahl, 2014). 
Additionally it is thought that zonisamide increases the release of dopamine and serotonin as 
well as acting as a carbonic anhydrase inhibitor (Stahl, 2006). Its side-effects may include 
marked sedation, a risk of life-threating skin rashes including Steven-Johnson syndrome, 
development of kidney stones and a risk of blood dyscrasias (Stahl, 2006). It is metabolised 
partly CYP450 3A4 and therefore its plasma concentration is liable to be affected by the 
inducers and inhibitors of this enzyme (Stahl, 2006). There is some low-level evidence for 
its use in treatment refractory anxiety from an open-label, pilot study with ten patients 
(Kinrys, Vasconcelos e Sa & Nery, 2007). Zonisamide, similarly to topiramate, can cause 
marked weight loss. It is used off-label for the treatment of obesity and psychotropic-







Criteria considered for studies in this review 
 
Types of studies 
 
The types of studies considered for this review were randomised, placebo controlled, 
trials of newer anticonvulsants in the treatment of GAD. Randomised controlled trials 
(RCT’s), with both placebo and active comparator arms were considered. However, 
data from the active comparator arms was not considered in this review. Only short-
term RCT’s were considered and relapse prevention studies were not included.  
 
Types of Participants 
 
Participants were considered if they suffered from GAD as defined by the criteria set 
out in the Diagnostic and Statistical Manual III (DSM III) (APA, 1980) or Diagnostic 
and Statistical Manual of Mental Disorders, Fourth Edition, (DSM-IV) (APA, 1994) or 
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision 
(DSM-IV-TR) (APA, 2000)   or the International Classification of Diseases-10 (ICD-10) 
of Mental and Behavioural Disorders (WHO, 1992). Participants were not restricted 
according to their age, gender or race. 
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Types of Intervention 
 
RCT’s of anticonvulsants brought to market from 1985 onwards were considered. This 
included RCT’s of felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, 
pregabalin, tiagabine, topiramate or zonisamide. RCT’s where the only intervention was 
a single anticonvulsant compared to a placebo control were included (allowing for the 
presence of active comparators if necessary). Trials where the anticonvulsant was used 
as an adjunctive treatment were not included. RCT’s which compared different dosages 
of a single anticonvulsant to a placebo control arm were considered. Data from 
multicentre trials was also considered.  
 
Types of outcome measures 
 
Studies with dimensional outcome measures were included if they provided symptom 
severity means and standard deviation data, or allowed the imputation of such data. It 
was decided on a case-by-case basis whether to include trials where certain established 
scales used in the study might have undergone minor modifications. Studies with 
dichotomous outcome measures were included if they provided post medication 




Reduction in symptom severity was measured by validated continuous outcome 
measures specific to GAD. The most widely used instrument in this regard is the 
Hamilton Anxiety Rating Scale (HAM-A) (HAMILTON 1960). The Clinical Global 
Impressions Scale-Improvement item (CGI-I) (Guy, 1976) is a global outcome measure 
widely used in clinical trials. It was used to determine treatment response (responders 
vs. non-responders). Responders on the CGI-I were defined as those having a score of 1 





Medication Acceptability. The total proportion of participants who withdrew from 
RCT’s due to treatment-related adverse events served as a surrogate measure of 
medication acceptability. If a more direct measurement of medication acceptability was 
made available by the RCT it was used instead. 
 
Search methods for identification of studies 
 
The search methods as described below were used while conducting the Cochrane 
Review “Newer anticonvulsants in the treatment of anxiety disorders” (Ipser & Stein, 
2006). The Cochrane search strategy was designed to provide results which included 
trials conducted on any of the anxiety disorders. The search results for this review will 
be obtained by extracting only the trials investigating GAD from the Cochrane search 
results. The dates in the search strategy below may not refer to the most recent search, 




1. The Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials 
Register (CCDANCTR-Studies) was searched with the following search strategy: 
CCDANCTR-Studies Diagnosis = Anxiety or Anxious or Phobi* or Panic or Obsess* or 
compulsi* or Post-Traumatic and Intervention = felbamate or gabapentin or lamotrigine 
or levetiracetam or oxcarbazepine or pregabalin or tiagabine or topiramate or 
zonisamide CCDANCTR-References 
Keyword = Anxiety or Anxious or Phobi* or Panic or Obsess* or compulsi* or Post-
Traumatic and Free-Text = felbamate or gabapentin or lamotrigine or levetiracetam or 
oxcarbazepine or pregabalin or tiagabine or topiramate or zonisamide 
 
2. The Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane 
Library Issue 2 2006) was searched. 
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3. Additional searches were carried out on MEDLINE via PubMed (January 1985 to 
December 2005), and through PsycINFO (1983 to 2005, Part B). The complete 
MEDLINE search query, as derived from the search strategy developed by Robinson 
(2002), is provided below: 
(randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized 
controlled trials [mh] OR random allocation [mh] OR double-blind method [mh] OR 
single-blind method [mh] OR clinical trial [pt] OR clinical trials [mh] OR (“clinical 
trial” [tw]) OR ((singl* [tw] OR doubl* [tw] OR trebl* [tw] OR tripl* [tw]) AND 
(mask* [tw] OR blind* [tw])) OR (“latin square” [tw]) OR placebos [mh] OR placebo* 
[tw] OR random* [tw] OR research design [mh:noexp] OR comparative study [mh] OR 
evaluation studies [mh] OR follow-up studies [mh] OR prospective studies [mh] OR 
cross-over studies [mh] OR control* [tw] OR prospectiv* [tw] OR volunteer* [tw]) 
NOT (animal [mh] NOT human [mh]) AND (anxiety disorder [mh:noexp] OR “anxiety 
disorder” [tw] OR phobic disorders [mh:noexp] OR obsessive- compulsive disorder 
[mh] OR “obsessive-compulsive” [tw] OR stress disorders, post-traumatic [mh:noexp] 
OR “post-traumatic” [tw]) AND (anti-convulsants [tw] OR anticonvulsants [tw] OR 
anticonvulsants [mh] OR anti-epileptics [tw] OR antiepileptics [tw] OR felbamate [tw] 
OR gabapentin [tw] OR lamotrigine [tw] OR levetiracetam [tw] OR oxcarbazepine [tw] 
OR pregabalin [tw] OR topiramate [tw] OR tiagabine [tw] OR zonisamide [tw]) The 
PsycINFO search strategy will include the following search query: (“randomisation” 
OR “randomization”) OR “controlled” AND (“anticonvulsants” OR “antiepileptics”). 
 
4. Ongoing trials were located using the metaRegister of Controlled Trials database 
(mRCT) (http://www.controlled-tri- als.com), as well as the National Institute of 
Health’s Computer Retrieval of Information on Scientific Projects (CRISP) service 
(1972-2005). The search terms “anticonvulsants OR antiepileptics” were entered into 
the search interface for these databases.  
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Reference Lists and Correspondence 
 
The bibliographies of all identified trials were scanned for additional studies. Published 
and unpublished trials were obtained from key researchers if possible, as identified by 
the frequency with which they were cited in the bibliographies of RCTs and open-label 
studies. Pharmaceutical companies were contacted if needed. They were identified 
through the source of funding cited in published RCTs, as well as the companies with 
which the authors were affiliated.  
 




Two independent raters (AK) and (LA) screened all trial data identified in the first 
search process. The trials were assessed based on information included in either the 
abstract or method section. RCTS’s were selected if both raters agreed that they 
satisfied the inclusion criteria as specified in the “Criteria for consideration of studies” 
section. One rater, (AK) collated the required data from the selected RCT’s as specified 
in the “Data extraction and management” section. Discussion was used to resolve any 
differences in the assessments made by the independent raters. If agreement could not 




Data Extraction and Management 
 
Data from each RCT was extracted and recorded in Covidence (Systematic Review 
Software) (Veritas Health Innovation, n.d.). This is a Web-based systematic review tool 
officially recommended by the Cochrane Collaboration for authors of systematic 
reviews (Babineau, 2014). It aids in citation screening, data extraction and assessing risk 
of bias amongst other features. The data collated within Covidence can be directly 
exported into Review Manager (RevMan) (Cochrane Collaboration, 2011). Covidence 
populates the necessary sections of a systematic review in RevMan. This includes 
descriptive information of the trials, risk of bias assessments and summary statistics of 
the outcome measures. RevMan was used to perform all statistical analyses, to export 
characteristics of studies, risk of bias assessments, graphs and data tables. 
 
The following specific data was gathered from each RCT: a description of the trials 
including the primary researcher, publication year and source of funding; the 
characteristics of the interventions including the number of participants randomised to 
the treatment and control groups, the total number of dropouts per group, dropouts due 
to adverse effects, dosages of medication, the time period over which medication was 
administered and the anticonvulsant used; the characteristics of trial methodology 
including the diagnostic criteria used, the inclusionary and exclusionary criteria used, 
the screening instruments used for the primary and comorbid diagnoses and the number 
of centres involved; the characteristics of participants including: the gender 
distribution, mean participant age and range, length of time since diagnosis with GAD, 
previous treatment with medication and baseline severity of GAD. 
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 The primary and secondary outcome measures including: the summary of continuous 
data with means and standard deviations, summary of dichotomous data reflecting the 
number of responders, incorporation of intention-to-treat (ITT) with last observation 
carried forward (LOCF) or completer/observed cases (OC) samples, the least amount of 
time needed in trial participation to qualify for inclusion in the LOCF sample and use 
of the mixed effects (ME) model (or another acceptable method) which provided an 
estimation of a drop-out participant’s outcome. Where certain important information 
was missing from particular studies, attempts were made to obtain it by emailing the 
investigators. 
 
Assessment of risk of bias of included studies 
 
The Cochrane Collaboration’s tool for assessing “risk of bias” was used (Higgins & 
Green, 2011). It assesses risk of bias in each of several key domains. In each domain the 
risk is classified as either “high”, “low” or “unclear” based on information provided in 
each study. The domains to assess bias across trials include sequence generation (selection 
bias), allocation concealment (selection bias), blinding of participants and personnel 
(performance bias), blinding of outcome assessors (detection bias), incomplete outcome data 
(attrition bias), selective outcome reporting (reporting bias) and other sources of bias. 
 




The following was calculated for continuous data: The mean difference (MD) (the 
Cochrane Collaboration prefer this term to “weighted mean difference”) was calculated 
for continuous data which was measured using the same scale. The standardised mean 
difference (SMD) was calculated where different scales were used to measure a specific 
outcome. To calculate the SMD, the differences between the means of the treatment and 





To present dichotomous data, the risk ratio (RR) (the Cochrane Collaboration prefer 
the use of this term to “relative risk”) of response to treatment was calculated for the 
dichotomous outcome of interest (which was CGI-I or related measure). Risk ratios 
were used in preference to odds ratios as odds ratios are interpreted less easily. When 
odds ratios are mistakenly interpreted as RR they tend to overestimate the size of 
treatment effect particularly when the outcome of interest occurs frequently (Higgins & 
Green, 2011). 
 
The number needed to treat for one additional benefit (NNTb) was determined for 
measures of treatment response on the CGI- I (or related measure). NNTb was 
calculated as the inverse of the absolute risk difference due to the medication 
intervention. NNTb was interpreted as the number of patients that must be treated with 
medication in relation to a control such that a further patient in the medication group 
would respond to treatment. A confidence interval for the NNTb could be calculated 
from the inverted limits of the confidence interval for the absolute risk difference. 
 
 When the inverse of the absolute risk difference, or the inverse of the confidence 
interval limits lead to a negative number, this indicated the direction of effect of the 
NNT. NNT values are always expressed as a positive whole number. Therefore, if the 
result obtained is negative the Cochrane Collaboration (Higgins & Green, 2011) advises 
using the term ‘number needed to treat for one additional harmful outcome’ (NNTh). 
This is interpreted to indicate a case where an intervention does not lead to an 
improvement but to a worsening of clinical status on the measure of treatment response.  
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Unit of Analysis Issues 
 
In the case where more than one fixed dose of an anticonvulsant was compared within a 
study to the same placebo group, it is necessary to take steps to avoid a unit-of-analysis 
error. This occurs as the same placebo group is counted more than once during the process 
of comparison to the different dosage subgroups. This leads to inaccurate results. There are 
multiple approaches suggested to overcome this problem. In this review, the method 
currently recommended by the Cochrane Collaboration was utilised. Subgroups within a 
trial are combined using a formula, specified in the Cochrane Handbook for Systematic 
Reviews of Interventions  (Deeks, Higgins & Altman, 2011), to generate a single, pair-wise 
outcome for the trial (Green, 2011). By having a single pair-wise outcome allows a trial to 
be included as part of a meta-analysis. The other options to overcome unit-of-analysis errors 
include selecting one pair of interventions from the trial and excluding the other subgroups, 
or undertaking a multiple-treatment meta-analysis (Green, 2011).  
 
Dealing with Missing Data 
 
Most studies use the number of patients randomised to each group at baseline as the 
intention-to-treat (ITT) sample. As Hoskins (2015) points out, some studies define a 
modified ITT (MIIT) sample as patients who have received at least one dose of medication 
and one post baseline assessment. This MIIT sample number might be the only one available 
and be used in the trial in calculating its outcome data. Dichotomous data was analysed via 
the ITT sample if it was provided by a trial alternatively the MITT sample was used. 
Summary statistics for continuous outcome measures were included in order of 
preference to the method used in their calculation. According to evidence by Verbeke 
(2009),  mixed effect models (ME) are more resistant to bias then analysis by last 
observation carried forward (LOCF). Based on this, (ME) were included first if 
possible, then LOCF and lastly observed cases (OC).  
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Assessment of heterogeneity 
 
The chi-squared test was used to assess heterogeneity. Evidence of heterogeneity was 
inferred if the chi-square test had a p-value of less then 0.10 as the chi-square statistic 
has low power when the number of trials is small (Deeks, 2002). The I2 heterogeneity 
statistic provided by RevMan was used to determine differences in effect size across trials 
that cannot be explained by chance alone (Higgins, Thompson, Deeks, et al., 2003; 
Cochrane Collaboration, 2011). I2 was interpreted following the guidelines laid out out in 
the Cochrane Handbook for Systematic Reviews of Interventions (Deeks, Higgins & Altman, 
2011). I2 allows the size of the heterogeneity of primary and secondary outcomes and their 
corresponding importance to be broadly assessed. I2 was interpreted as follows: 0% - 40% - 
might not be important; 30%-60% - may represent moderate heterogeneity; 50% -90% - may 
represent substantial heterogeneity; 75%- 100% - considerable heterogeneity (Deeks, 
Higgins & Altman, 2011). 
 
Assessment of Reporting Bias 
 
The fact that a study is published does not necessarily imply that it is of high quality. 
Publication may suggest the possibility of particular biases. (Easterbrook, Berlin, 
Gopalan, et al., 1991; Dickersin, Min & Meinert, 1992) (Scherer, Dickersin & Langenberg, 
1994). A funnel plot of treatment response will be generated and visually assessed for 
asymmetry. An asymmetrical funnel plot may suggest the possibility of small-sample 





The random effects statistical model was used to get categorical and continuous 
treatment effects. Within-study sampling error and between-study variation is included 
in the random effects model. This was used to calculate the precision of the confidence 
interval around the overall effect size. In comparison the fixed effects model uses only 
within-study variation. Outcomes were expressed as either an average effect size for 




Ethics approval was not, in principal, required for a systematic review such as this. 
However, there was mandatory documentation, that was required by the University of 
Cape Town Human Research Ethics Committee, for this minor dissertation. This 








Results of the Search 
 
Three separate searches were made of the The Cochrane Collaboration Depression, Anxiety 
and Neurosis Controlled Trials Register (CCDANCTR) and clinicaltrials.gov website over 
a three-year period for this review. The last search of the CCDANCTR was up-to-date as of 
the 31/07/2013 and clinicaltrials.gov as of the 19/08/2013. According to the Cochrane 
Collaboration (Higgins & Green, 2011) a systematic review should be considered for 
updating approximately two years since the date of the last search. It would be optimal to 
update the search as it has been more than two years since the last Cochrane Collaboration 
search. 
 
  It was not possible to gain access to the Trials Search Co-ordinator of the Cochrane 
Depression, Anxiety and Neurosis Group to perform an updated search. The mini-
dissertation was based upon the larger official Cochrane Systematic Review entitled “Newer 
anticonvulsants in the treatment of anxiety disorders” (Ipser & Stein, 2006) which is yet to 
be completed. By the time the most updated search was performed for this dissertation, the 
author of this dissertation was no longer planning to work as an author on the official 
Cochrane Systematic Review and planned to pass it on. Therefore, requesting further 
searches by the Trials Search Co-ordinator for this dissertation was not considered to be a 
viable option. Therefore, an independent search was conducted of PubMed on the 
16/05/2016 to check for any further studies that may have occurred in this subject area. The 
following PubMed search query used:  
((((("randomized controlled trial"[Publication Type]) OR "review"[Publication Type]) OR 
"meta analysis"[Publication Type]) AND anxiety disorders[MeSH Terms]) AND 
anticonvulsants[MeSH Terms]).  
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From this search there were no additional citations of RCT’s, reviews or meta-analyses 
identified, of anticonvulsants in the treatment of GAD, after the date of the last official 
Cochrane Collaboration search. Therefore, no new data was added. The systematic review 
and meta-analysis is considered up-to-date as of the 16/05/2016.  
 
 287 citations were generated in the search process. Each citation was screened, using the 
title and abstract, by two different reviewers (AK) and (LA). 228 citations were removed 
which included 83 duplicates and 145 trials not meeting inclusion criteria. 59 papers were 
retrieved for full-text review. 29 were excluded as they did not meet one or more inclusion 
criteria. Only one record of an unpublished RCT on GAD using anticonvulsants was found. 
Pfizer conducted this unpublished RCT in 2003 comparing pregabalin, lorazepam and 
placebo in GAD (Study 1008-025 (Pfizer, data on file)). Attempts were made to obtain this 
data but were unsuccessful and the trial had to be excluded. All the remaining included trials 
were published in journals. 30 anxiety disorder full text papers remained. A further 20 full 
text papers were removed on closer inspection. This consisted of that 17 papers that did not 
concentrate on GAD and 3 other papers on GAD which did not meet various other inclusion 
criteria. Ten full text papers on GAD remained. One of the full text papers, Pollack 2008, 
consisted of 3 independent RCTs. Therefore, there were 12 RCT’s from 10 full text papers 
included in the systematic review and meta-analysis. The flow diagram in Figure 1 
graphically represents the search process which was conducted as recommended by the 









Updated Search 29/12/2011 – 30/08/2012 CCDAN
CCDANCTR
References tagged to studies (10 studies, 14 
references)
Additional untagged references (n = 7)
Clinicaltrials.gov (all years to 23/10/2012) (n=3)
Third Search
Updated Search 31/08/2012 – 31/07/2013
CCDANCTR (n=21)
ClinicalTrials.gov (23/10/2012 – 19/08/2013) (n=3)
First Search
• CCDANCTR (28 Dec 2011) = 174 references
• Clinicaltrials.gov (3rd Feb 2012) = 35 references
No. of Records Excluded Total = 228
Reasons for exclusion:
Did not meet Inclusion Criteria: 145
Duplicates: Removed 83 
287 Citations Retrieved 
in Total
Screened by Title and 
Abstract
59 Papers Retrieved for Full Text Review
29 Full Text Papers Excluded
Various reasons for exclusion including:
• -Study not randomised
• -Study not placebo controlled (active comparator is allowed 
  if placebo is present in addition).
• -Study is open-label. 
-Study is not short term RCT (no relapse prevention 
studies)  
-No published or unpublished data
          could be traced (even after Emailing Principal Investigators/
  Companies)
• -Post hoc Analyses
• -Complex/intricate study design
• -Starting participants don’t have a DSM IV Anxiety Disorder
• -Non-relevant outcomes
• -Studies still on-going
• -Some Additional Duplicates Found
30 Full Text Papers on Anxiety Disorders 
retrieved in total 
10 Full Text Papers on GAD Included in the 
Review  
12 RCT’s on GAD met all Review Criteria and 
were included in the Meta-Analysis, even though 
only 10 Full Text Papers are included. (N.B This 
is by taking into account that Pollack 2008 is a 
single paper but contains 3 independent RCT’s) 
Pregabalin = 8 RCT’s Tiagabine = 4 RCT’s
-20 Full Text Papers Excluded: 
 
-17 Papers excluded as did not focus on 
GAD   
-3 Full Text Papers on GAD excluded as:   
-one was an open-label trial.   
-one was a relapse prevention trial.   
-one trial had no placebo arm (only an active 
comparator) 
 39 




Twelve studies were included in the systematic review and meta-analysis. A summary of the 
baseline demographic, clinical characteristics and study ID of the included studies are 
presented in Table 1 below. The included studies will be referred to within the text by their 
Study ID in bold lettering in the format “Author Year”. 
 
Study ID and In-Text Citation for the Included Studies 
 
• Pande 2003  (Pande, Crockatt, Feltner, et al., 2003) 
• Feltner 2003 (Feltner, Crockatt, Dubovsky, et al., 2003) 
• Pohl 2005 (Pohl, Feltner, Fieve, et al., 2005) 
• Pollack 2005 (Pollack, Roy-Byrne, Van Ameringen, et al., 2005) 
• Rickels 2005 (Rickels, Pollack, Feltner, et al., 2005) 
• Montgomery 2006 (Montgomery, Tobias, Zornberg, et al., 2006) 
• Montgomery 2008 (Montgomery, Chatamra, Pauer, et al., 2008) 
• Pollack 2008(a, b and c) (Pollack, Tiller, Xie, et al., 2008) 
• Kasper 2009 (Kasper, Herman, Nivoli, et al., 2009) 




All twelve studies were RCT’s utilising a parallel-group design. Pollack 2008(a, b and c) 
consisted of three independent RCT’s described in one publication. All included trials were 
RCT’s with a placebo arm with some containing an additional active comparator arm. The 
average duration of the trials was 7.2 weeks with the shortest trials lasting 4 weeks and the 
longest trials 10 weeks. 
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Setting and Sponsorship Source 
 
Six studies were conducted only in the United States (U.S) and one study had sites in Europe 
and the U.S. One study was conducted in Romania, and two large studies were conducted 
across multiple European countries including Belgium, Canada, France, Ireland, the 
Netherlands, Spain, Sweden, Austria, Germany and the United Kingdom. The average 
number of sites involved in each study was 35.5. Eleven of the twelve studies were funded 




4001 participants are included in the meta-analysis consisting of 2516 participants in the 
anticonvulsant group and 1485 in the placebo group. These numbers are of ITT or MITT 
samples as listed in the publications. The total number of participants sometimes differed 
across summary outcomes within the same trial. This is due to the fact that some trials 
specified different MITT numbers for different outcomes. Whichever MITT they utilised for 
the specific outcome was used in the meta-analysis.  The average age of participants was 43 
years. The average percentage of female participants was 60.4%.  
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Table 1.  Summary of Characteristics of Included Studies 
 
Trial ID  Title 
Feltner 2003 
A randomized, double-blind, placebo-controlled, fixed-dose, 
multicentre study of pregabalin in patients with generalized anxiety 
disorder 
Pande 2003 Pregabalin in generalized anxiety disorder: A placebo-controlled trial 
Rickels 2005 
Pregabalin for treatment of generalized anxiety disorder: a 4-week, 
multicentre, double-blind, placebo-controlled trial of pregabalin and 
alprazolam 
Pohl 2005 
Efficacy of pregabalin in the treatment of generalized anxiety 
disorder: double-blind, placebo-controlled comparison of BID versus 
TID dosing 
Pollack 2005 
The selective GABA reuptake inhibitor tiagabine for the treatment of 
generalized anxiety disorder: Results of a placebo-controlled study 
Montgomery 
2006 
Efficacy and safety of pregabalin in the treatment of generalized 
anxiety disorder: a 6-week, multicentre, randomized, double-blind, 
placebo-controlled comparison of pregabalin and venlafaxine 
Montgomery 
2008 
Efficacy and safety of pregabalin in elderly people with generalised 
anxiety disorder 
Pollack 2008 (a, 
b and c) 
Tiagabine in adult patients with generalized anxiety disorder: results 
from 3 randomized, double-blind, placebo-controlled, parallel-group 
studies 
Kasper 2009 
Efficacy of pregabalin and venlafaxine-XR in generalized anxiety 
disorder: Results of a double-blind, placebo-controlled 8-week trial. 
Ionescu 2010 
The efficacy and the tolerability of pregabalin in the case of adults 






Trial ID  Journal Industry-Funded 
Feltner 2003 
Journal of Clinical 





American Journal of Psychiatry: Am. 
J. Psychiatry 2003;160(3):533-540 
Yes 
Rickels 2005 























(a, b and c) 
Journal of clinical 
psychopharmacology 
2008;28(3):308-316 
Yes (all 3 studies were 





















Feltner 2003 204 67 Pregabalin 37,30 
Pande 2003 139 69 Pregabalin 36,40 
Rickels 2005 270 91 Pregabalin 39,00 
Pohl 2005 255 86 Pregabalin 40,00 
Pollack 2005 130 130 Tiagabine 37,25 
Montgomery 
2006 
207 101 Pregabalin 43,30 
Montgomery 
2008 
77 96 Pregabalin 72,30 
Pollack 2008 
(a, b and c) 
1057 662 Tiagabine 38,94 
Kasper 2009 121 128 Pregabalin 40,35 












was Conducted  
Feltner 2003 51,03% 4 4 U.S 
Pande 2003 58,17% 4 5 U.S 
Rickels 2005 63,25% 4 29 U.S 
Pohl 2005 60,00% 6 19 U.S 
Pollack 2005 57,00% 8 32 U.S 
Montgomery 
2006 








77,00% 8 72 13 sites in the 
U.S and 69 
sites in Europe 
Pollack 2008 (a, 
b and c) 
60,38% 10 Unclear U.S 











Trial ID 	 Design Medication Dosages  
Feltner 2003 RCT Pregabalin 50mg TID & Pregabalin 200mg TID 
Pande 2003 RCT 
Pregabalin 150mg/day Total (50mg TID) & Pregabalin 
600mg/day Total (200mg TID) 
Rickels 2005 RCT 
Pregabalin 300mg/day Total (Dosed in TID Regimen) & 
Pregabalin 450mg/day Total (Dosed in TID Regimen) & 
Pregabalin 600mg/day Total (Dosed in TID Regimen) 
Pohl 2005 RCT 
Pregabalin 200mg/day Total (100mg BID) & Pregabalin 
400mg/day Total (200mg BID) & Pregabalin 450mg/day Total 
(150 TID) 




Pregabalin 400mg/day In Total Dosed in BID Regimen & 
Pregabalin 600mg/day In Total Dosed in Bid Regimen 
Montgomery 
2008 
RCT Pregabalin (150- 600mg) Flexibly Dosed 
Pollack 2008 
(a, b and c) 
RCT 
Tiagabine 12mg/Day Total (Fixed Dosage in BID Regimen), 
Tiagabine 8mg/Day Total (Fixed Dosage in BID Regimen) & 
Tiagabine 4mg/Day Total (Fixed Dosage in BID Regimen) in 
Study “a”. Tiagabine (4mg-16mg Total Flexibly Dosed in BID 
Regimen) in Study “b”. Tiagabine (4mg-16mg Total Flexibly 
Dosed in BID Regimen) in Study c. 
Kasper 2009 RCT Pregabalin (300 -600mg/day Flexibly Dosed in BID Regimen) 





The inclusion criteria varied across the studies, with some studies more stringent than others. 
The permitted age of participants was 18 years or older with some studies setting an upper 
limit of 65 years old and one study requiring patients only older then 65 years. Participants 
had to meet DSM-IV (APA, 1994) or DSM-IV-TR (APA, 2000) criteria for GAD with most 
studies using the Mini-International Neuropsychiatric Interview (Sheehan, Lecrubier, 
Sheehan, et al., 1998) to confirm the diagnosis. Across most studies, patients had to have a 
HAM-A total score >= 20 at screening and baseline visits.  
 
In patients with comorbid psychiatric disorders, GAD was required to be the primary 
psychiatric disorder as judged by the investigator. In some studies patients were required to 
have a Covi Anxiety Scale (Lipman, 1982) score of >=9 and a Raskin Depression Scale 
(Raskin, Schulterbrandt, Reatig, et al., 1969) score of <= 7 to confirm that anxiety 
symptoms outweighed depression symptoms. The majority of studies required patients to be 
free of psychotropic medication for two weeks prior to enrolment or five weeks in the case 
of fluoxetine. Most trials permitted no psychotropic medications during the trials although 





Exclusion criteria were numerous and varied across the trials. Patients were excluded if they: 
were diagnosed with from additional Axis I pathology excepting dysthymia, simple phobia, 
social phobia, somatization disorder or previous episodes of major depression disorder; were 
suffering from a current episode of major depression; had severe personality disorders such 
as antisocial or borderline; suffered from substance abuse or dependence, with an episode 
occurring in the previous six months (some studies included a urine drug screen); were 
considered a suicide risk judged on history and examination or scored greater than or equal 




 Some studies specifically stated that patients with a diagnosis of schizophrenia, 
schizoaffective disorder, other psychotic disorders or bipolar disorders were excluded. 
Particular studies stated additional physical conditions as exclusionary criteria including: 
any serious haematological, autoimmune, endocrine, cardiovascular, renal, hepatic, 
gastrointestinal or neurological disorder including any history of a seizures. All studies 
excluded women who were pregnant or lactating. Most studies specified that women in their 




Pregabalin was used as the intervention in eight of the studies and tiagabine in the remaining 
four studies. Various dosage regimes were used which appear in Table 1. Five pregabalin 
studies placed the participants randomly into separate fixed-dosage groups with differing 
dosage regimes. The remaining three pregabalin studies allowed a flexible dosing regime 
which ranged from 150mg/day to 600mg/day. There were three flexibly dosed trials of 
tiagabine and one fixed dosage regimen trial. The dosage of tiagabine ranged from 2mg/day 
up to 16mg/day. The fixed dosage study specifically had groups assigned to 4mg, 8mg and 
12mg/day. For studies with multiple treatment dosage arms, the subgroups were combined 





All the studies used the Hamilton Anxiety Rating Scale (HAM-A) (HAMILTON, 1960) for 
the primary continuous outcome. This allowed for the mean difference (MD) as opposed to 
the SMD to be used in the meta-analysis. All the trials, with the exception of Pande 2003 
and Ionescu 2010 provided complete data to allow calculation of the dichotomous outcome 
of treatment response utilising the CGI-I. Pande 2003 provided unclear information on the 
number of responders in the 150mg pregabalin group, but provided clear data for its other 
groups. Ionescu 2010 was the only trial which provided no data to allow the calculation of 
treatment response. All the trials provided the necessary data to allow for calculation of 
treatment acceptability by using the RR of drop-outs due to treatment-adverse effects. The 
number needed to treat for an additional beneficial outcome (NNTb) could be calculated for 
the anticonvulsants as a group, as well as for pregabalin and tiagabine alone. 
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 There was sufficient data to allow a meta-analysis to be undertaken for the two primary 
outcomes and the single secondary outcome. The summary statistics that were obtained for 
all outcomes in the meta-analysis were expressed as an effect estimate with a 95% 
confidence interval. Forest plots were generated for the primary outcomes and the secondary 
outcome of the anticonvulsants as a group, pregabalin considered alone and tiagabine 
considered alone. All the forest plots are displayed below in the main body of the text. The 
full data tables, are displayed in the Appendices. The data tables contain all the outcome 




Excluded Studies mainly consisted of trials not assessing GAD using the criteria sets as 
specified “Methods” section. Other studies were excluded for not using the specified 
anticonvulsants as interventions. Many studies were excluded for not being randomised or 
not having a placebo control arm. Other finer details excluded studies. For example, three 
studies in particular were excluded and are presented below in Table 2. Rosenthal (2003) 
was excluded for possessing no placebo arm. Feltner (2008) was excluded as it was a long-
term relapse prevention study. Rickels (2012) was excluded as it used an anticonvulsant as 
adjunctive treatment. There were no ongoing studies or studies awaiting classification that 
were apparent at the time of the last search. 
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Risk of Bias in Included Studies 
 
The ‘risk of bias’ (methodological quality) was assessed in the included studies. This was 
done according to the ‘Risk of Bias tool’ specified by the Cochrane Collaboration (Higgins 
& Green, 2011). Bias was assessed across the recommended domains: sequence generation 
(selection bias), allocation concealment (selection bias), blinding of participants and 
personnel (performance bias), blinding of outcome assessors (detection bias), incomplete 
outcome data (attrition bias), selective outcome reporting (reporting bias) and other sources 
of bias. Bias was rated as unclear, low or high risk in each domain. Displayed below in 
Figure 2 is a Risk of Bias Graph which presents judgements about each risk of bias domain 
expressed as percentages across all the included studies. Figure 3 displays the Risk of Bias 
Summary which presents judgements on each risk of bias item for each of the included 
studies. A brief commentary on the ‘Risk of Bias’ for each study follows.  
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Figure 2: Risk of Bias Graph, displays judgements about each risk of bias domain expressed 




Figure 3: Risk of Bias Summary, displays judgements on each risk of bias item for each of 
the included studies. Key: Yellow circle containing ‘?’ = unclear risk of bias; Green circle 







Random sequence generation (Selection Bias) 
 
Feltner 2003, Pande 2003, Pohl 2005, Pollack 2005, Rickels 2005, Montgomery 2006, 
Montgomery 2008, Pollack 2008(a, b and c) and Ionescu 2010 did not make it clear in 
their texts’ how a randomised sequence was generated in the trials. Therefore, the risk of 
selection bias in all the the above trials was judged to be unclear. Only Kasper 2009 made it 
clear how sequence generation was performed in the trial stating that a computer-generated 
sequence was utilised for the randomisation process. Therefore, Kasper 2009 was the only 
trial to receive a rating of low in regards to the risk of selection bias from sequence 
generation. 
 
Allocation Concealment (Selection Bias) 
 
Feltner 2003, Pande 2003, Pohl 2005, Pollack 2005, Rickels 2005, Montgomery 2006, 
Montgomery 2008, Kasper 2009 and Ionescu 2010 made no comment in their texts, on any 
procedures used to conceal allocation. Therefore, all the above trials received a rating of 
unclear regarding the risk of selection bias from allocation concealment. Only Pollack 
2008(a, b and c) made it clear how allocation concealment was performed in all three trials, 
stating that the sponsors generated the randomization sequence for the allocation and then 
distributed a code to the study personnel. Therefore, Pollack 2008(a, b and c) were the only 





Blinding of outcome assessment (Detection Bias) 
 
 Feltner 2003, Pande 2003, Pohl 2005, Pollack 2005, Rickels 2005, Montgomery 2006, 
Montgomery 2008, Pollack 2008(a, b and c) all describe their study design as “double-
blinded”. However, none of these trials describe in necessary detail what procedures, if any, 
were used to ensure the blinding of the outcome assessors. This makes the risk of detection 
bias in these trials unclear. Regarding blinding of outcome assessors in Kasper 2009, it is 
specifically stated that “investigators” assessed the outcomes during “double-blind 
treatment”. Given the more definite assurance and the way it is unambiguously stated in the 
manuscript, the risk of detection bias in Kasper 2009 was judged to probably be low. 
 
 With regards to the blinding of outcome assessors, Ionescu 2010 does not actually state, in 
the text, if the trial was single or double-blinded. The protocol of Ionescu 2010 was not 
accessible and the authors were not contactable. For the purpose of this review, it was 
assumed, because Ionescu 2010 has a placebo arm, that by implication the participants were 
blinded somehow, and hence, the study is at least single-blinded. However, it is not clear 
from the text, who the outcome assessors were and if they were blinded. The risk of 
detection bias would only be valid to comment on if Ionescu 2010 was a double-blinded 
study. Nevertheless, if it is assumed the outcome assessors were indeed blinded, from the 
text available, the risk of detection bias in Ionescu 2010 would be judged as unclear. 
 
Blinding of participants and personnel (Performance Bias) 
 
Feltner 2003, Pande 2003, Pollack 2005, Rickels 2005, Montgomery 2006, Montgomery 
2008, Pollack 2008 (a, b and c), Kasper 2009 and Ionescu 2010 were all judged to have an 
unclear risk of performance bias. None of these trials described in sufficient detail, or were 
clear and definitive enough in describing, how participants and personnel were blinded. 
Only Pohl 2005 described, in sufficient detail, methods used to ensure the blinding of 
participants and personnel. It specified that all medication was blister packed and provided 




Incomplete Outcome Data (Attrition Bias) 
 
Table 3 briefly overviews the factors involved in the assessment of Incomplete Outcome 
Data which allows the risk of attrition bias in the included studies to be judged. One feature 
to note is that a comparison of the characteristics of drop-outs compared to study completers 
is important for studies to perform. Such a comparison allows the extent to which attrition 
bias could affect study outcomes to be assessed. Only one of the included studies, 
Montgomery 2006, mentioned this in their text.  
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Table 3 Assessment of Incomplete Outcome Data (Attrition Bias) 





















Feltner 2003 27.7% Yes Fair No Unclear 
Pande 2003 22.1% Yes Fair No Unclear 
Pohl 2005 27.8% Yes Good No Low 
Pollack 2005 27.5% Yes Poor No High 
Rickels 2005 21.5% Yes Good No Low 
Montgomery 
2006 
21.7% No –But 
attrition rates 
are fairly low 
overall 








26.5% Yes Good No Low 
Pollack 
2008(a, b and 
c) 
34.3% No Fair No High 
Kasper 2009 27.3% Yes Good No Low 




Selective Reporting (Reporting Bias) 
 
With regards to selective outcome reporting, we did not have access to the protocol of any of 
the included studies. Therefore, we could not comment with certainty on potential selective 
reporting in the published manuscripts. Hence, the risk of reporting bias in all the included 
studies was judged to be unclear.  
 
Other Potential Sources of Bias 
 
No other potential sources of bias were thought to be present in the publications of all the 
included studies. However, without more information or data to confirm this, it is not certain 
that other sources of bias do not actually exist in each trial. Therefore, the risk of other 
potential sources of bias in all the included studies was judged to be unclear.  
 
Effects of Interventions 
 
For the primary and secondary outcome comparisons, in all cases, the component trials (a, b 
and c) of Pollack 2008 were assessed as three separate trials  
 
Primary Outcomes: Continuous Outcome 
 
The following information applies to all the continuous primary outcome comparisons: a 
random effects meta analysis was generated using the mean difference (MD) as an effect 
measure expressed as an effect estimate with a 95% confidence interval (CI); the mean 
change in HAM-A total score at study end-point was used to reflect the reduction in 
symptom severity in GAD; the MD of the mean change in HAM-A scores between 
intervention and placebo groups was utilised as the effect measure and a negative MD 
favoured the intervention group relative to the placebo group. 
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The Anticonvulsant Group (pregabalin and tiagabine combined) compared to 
Placebo in Treating GAD 
 
A meta-analysis comparing the anticonvulsant group to placebo, was performed on twelve 
studies containing 3986 participants. Figure 4 displays the related forest plot. The overall 
effect estimate was significant and in favour of the anticonvulsant group with an MD of -
2.10 [-2.83, -1.36] (95% CI) compared to placebo. There was evidence of moderate 
heterogeneity in the overall results (Chi
2
 p-value = 0.03 and I
2
 = 48%).  
 
Pregabalin compared to Placebo in Treating GAD 
 
A meta-analysis comparing pregabalin to placebo was performed on eight studies containing 
2007 participants. Figure 7 displays the related forest plot. The overall effect estimate was 
significant and in favour of the pregabalin group with a MD of -2.86 [-3.52, -2.21] (95% CI) 
compared to placebo. There was no evidence of heterogeneity across the studies (Chi
2
 p-
value = 1.00 and I
2
 = 0%). 
 
Tiagabine compared to Placebo in Treating GAD 
 
A meta-analysis comparing tiagabine to placebo was performed on four studies containing 
1979 participants. Figure 10 displays the related forest plot. The overall effect estimate was 
not statistically significant with a MD of -0.58[-1.41, 0.25] (95% CI) of tiagabine compared 
to placebo. There was no evidence of heterogeneity in the overall results (Chi
2
 p-value = 
0.54 and I
2
 = 0%). 
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Primary Outcomes: Dichotomous Outcome  
 
The following information applies to all the dichotomous primary outcome comparisons: a 
random effects meta-analysis was generated using risk ratio (RR) as an effect measure 
expressed as an effect estimate with a 95% confidence interval (CI); treatment response 
(responders versus non-responders) in the intervention and placebo groups was calculated 
using the CGI-I by defining a responder as those having a CGI-I score of 1 equalling “very 
much” improved or 2 equalling “much” improved; RR >1 of treatment response favoured 
the intervention group relative to the placebo group; NNTb was calculated expressed for 
each comparison as a positive whole number with a 95% CI; NNTh was if used to indicate 
that a negative number was generated during the NNT calculation and Ionescu 2010 was not 
estimable as it provided no outcome data for treatment response. 
 
The Anticonvulsant Group compared to Placebo in Treating GAD 
 
A meta-analysis comparing the anticonvulsant group to placebo was performed on eleven 
studies containing 4000 participants. Figure 5 displays the related forest plot. The overall 
effect estimate of treatment response was significant and in favour of the anticonvulsant 
group (RR 1.23 [1.12, 1.35] 95% CI) relative to placebo.  
Heterogeneity was not suggested by the Chi
2
 test which had a p-value of 0.17. The I
2
 
statistic was 29% reflecting a magnitude of heterogeneity which might not be important. 
NNTb was calculated to be 11 [16,8] 95% CI.  
 
Pregabalin compared to Placebo in Treating GAD 
 
A meta-analysis comparing pregabalin to placebo was performed on seven studies 
containing 2021 participants. Figure 8 displays the relevant forest plot. The overall effect 
estimate of treatment response was significant and in favour of pregabalin (RR 1.35 [1.21, 
1.50] 95% CI) relative to placebo. There was no indication of heterogeneity across trials 
(Chi
2
 test (p = 0.42); I
2
 = 0%). NNTb was calculated to be 7 [10,5] 95% CI.  
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Tiagabine compared to Placebo in Treating GAD  
 
A meta-analysis comparing tiagabine to placebo was performed on four studies containing 
1979 participants. Figure 11 displays the related forest plot. The overall effect estimate of 
treatment response of tiagabine compared to placebo was not statistically significant (RR 
1.09 [0.98, 1.22] 95% CI). There was no indication of heterogeneity across the trials (Chi
2
 
test p-value = 0.75); I
2
 = 0%). NNTb was calculated to be 25 [227(NNTh), 12(NNTb)] 95% 
CI.  
 
Secondary Outcome: Dichotomous Outcome 
 
The following information applies to all the dichotomous secondary outcome comparisons: a 
random effects meta-analysis was generated using risk ratio (RR) as an effect measure 
expressed as an effect estimate with a 95% confidence interval (CI); treatment acceptability 
was assessed using the total proportion of participants who withdrew from the trial due 
to treatment-related adverse events in the intervention and placebo groups respectively and 
a RR >1 of treatment acceptability favoured the placebo group relative to the intervention 
group. 
 
Treatment Acceptability of the Anticonvulsant Group Compared to Placebo in 
GAD 
 
A meta-analysis comparing the anticonvulsant group to placebo was performed on twelve 
studies containing 4110 participants. Figure 6 displays the related forest plot. The overall 
effect estimate of treatment acceptability was significant and was not in favour of the 
anticonvulsant group compared to placebo (RR 1.49 [1.18, 1.88] 95% CI). Heterogeneity 
was not suggested by the Chi
2
 test which had a p-value of 0.31. The I
2
 statistic was 14% 
which is in keeping with a level of heterogeneity which might not be important. 
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Treatment Acceptability of Pregabalin Compared to Placebo in GAD 
 
A meta-analysis comparing pregabalin to placebo was performed on eight studies containing 
2054 participants. Figure 9 displays the related forest plot. The overall effect estimate of 
treatment acceptability of pregabalin relative to placebo was not statistically significant (RR 





 =0).  
 
Treatment Acceptability of Tiagabine Compared to Placebo in GAD 
 
A meta-analysis comparing tiagabine to placebo was performed on 4 studies which included 
2056 participants. Figure 12 displays the related forest plot. The overall effect estimate of 
treatment acceptability was significant and not in favour of tiagabine relative to placebo (RR 
1.95 [1.29, 2.93] 95% CI). There was no evidence of heterogeneity inferred from the Chi
2
 
statistic with the p-value = 0.2. However, I
2
 = 36%, suggesting a level of heterogeneity that 






Figure 4: Forest plot of Comparison of the Anticonvulsant Group Compared to Placebo in 
Treating GAD. Outcome: Reduction in Symptom Severity as Measured by Mean Change in 




Figure 5: Forest plot of the Anticonvulsant Group Compared to Placebo in Treating GAD. 
Outcome: Risk Ratio of Treatment Response (Responders vs Non-Responders on CGI-I 





Figure 6: Forest plot of Treatment Acceptability of the Anticonvulsant Group Compared to 
Placebo in Treating GAD. Outcome: Risk Ratio of Drop-Outs Due to Treatment-Adverse 




Figure 7: Forest plot of Comparison of Pregabalin Compared to Placebo in Treating GAD. 
Outcome: Reduction in Symptom Severity as Measured by Mean Change in HAM-A Total 




Figure 8: Forest plot of Pregabalin Compared to Placebo in Treating GAD. Outcome: 
Relative Risk (Risk Ratio) of Treatment Response (Responders vs Non-Responders on CGI-










Figure 9: Forest plot of Treatment Acceptability of Pregabalin Compared to Placebo in 
Treating GAD. Outcome: Relative Risk (Risk Ratio) of Drop-Outs Due to Treatment-




Figure 10: Forest plot of Comparison of Tiagabine Compared to Placebo in Treating GAD. 
Outcome: Reduction in Symptom Severity as Measured by Mean Change in HAM-A Total 
Score in The Tiagabine Compared to Placebo Group. 
 
 
Figure 11: Forest plot of Tiagabine Compared to Placebo in Treating GAD. Outcome: 
Relative Risk (Risk Ratio) of Treatment Response (Responders vs Non-Responders on CGI-




Figure 12: Forest plot of Treatment Acceptability of Tiagabine Compared to Placebo in 
Treating GAD. Outcome: Relative Risk (Risk Ratio) of Drop-Outs Due to Treatment-
Adverse Effects in Tiagabine Compared to Placebo Group. 
 
Assessment of Reporting Bias (Publication Bias) 
 
It is recommended by the Cochrane Collaboration (Higgins & Green, 2011) that a funnel 
plot should only be used in meta-analysis with ten or more studies as fewer studies 
could lead to misleading results. This meta-analysis contained twelve studies and 
therefore a funnel plot was generated. The funnel plot displayed below in Figure 13 is 
generated from the risk ratio of treatment response of anticonvulsants compared to placebo. 
It was visually assessed to detect any small-trial (small-sample) effects which may include 
publication bias.  
 
It appears some asymmetry may be present when comparing the lower left corner to the 
lower right corner. However, it has been pointed out by Simmonds (2015) that visually 
assessing a funnel plot is a purely subjective process and can easily be misinterpreted 
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mainly when the number of studies is low. No inferences regarding possible publication 
bias will be made from the visual assessment of this funnel plot taking into account the 
relatively low number of trials and the above limitations associated with visual 
assessment. Formal statistical tests of asymmetry were not performed in this review. 
 
Figure 13: Funnel plot of Treatment Response of the Anticonvulsant Group Compared to 
Placebo in Treating GAD Visually Assessed to Detect Any Small-Trial Effects Including 





Summary of Main Results 
This systematic review and meta-analysis investigated the use of the newer anticonvulsants 
in generalised anxiety disorder and involved twelve short term randomised placebo 
controlled trials. Eight RCT’s involved pregabalin and four involved tiagabine. The main 
result in the meta-analysis was that pregabalin demonstrated significant efficacy relative to 
placebo in reducing symptom severity and treatment response rates in GAD. In contrast, 
tiagabine failed to show significant efficacy in the primary outcomes and displayed 
significantly poor treatment acceptability. The two agents, when considered together, did 
display significant efficacy in both primary outcomes. However, the superior efficacy of 
pregabalin most likely compensated for the somewhat poorer efficacy of tiagabine.  
 The anticonvulsant group (comprising pregabalin and tiagabine) was found to be superior to 
placebo when using reduction of HAM-A scores as a continuous outcome with an overall 
MD of -2.10 [-2.83, -1.36] (95% CI) compared to placebo. The anticonvulsant group 
demonstrated significant superiority to placebo in treatment response utilising the CGI-I to 
create this dichotomous outcome. The overall risk ratio of treatment response was 1.23 
[1.12, 1.35] (95% CI), with a RR > 1 favouring the anticonvulsant group. The NNTb for the 
anticonvulsant group versus placebo was calculated to be 11 [16,8] 95% CI. The treatment 
acceptability of the anticonvulsant group was found to be significantly inferior to placebo 
with an overall risk ratio of 1.49 ([1.18, 1.88] 95% CI), where in this case a RR >1 did not 
favour the anticonvulsants. 
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Pregabalin was found to have significant results showing it to be more efficacious than 
placebo in terms of reduction of symptom severity (MD -2.86 [-3.52, -2.21] (95% CI) and in 
terms of treatment response (RR 1.35 [1.21, 1.50] 95% CI). The NNTb for pregabalin was 
calculated to be 7 [10,5] 95% CI. In terms of treatment acceptability, pregabalin produced a 
non-significant result compared to placebo (RR 1.23 [0.92, 1.65] 95% CI). Therefore, the 
treatment acceptability of pregabalin could not be shown, with statistical significance, to be 
inferior to placebo. 
 
 Tiagabine did not demonstrate statistically significant efficacy compared to placebo in 
terms of reduction of symptom severity (MD of -0.58[-1.41, 0.25] 95% CI) and in treatment 
response (RR 1.09 [0.98, 1.22] 95% CI). NNTb for tiagabine was calculated to be 25 
[227(NNTh), 12(NNTb)] (95% CI). Tiagabine had a statistically significant unfavourable 
result of treatment acceptability relative to placebo (RR 1.95 [1.29, 2.93] 95% CI).  
 
Consistencies and Inconsistencies with Other Studies or Reviews 
 
This study is consistent with the findings in the review by Mula (2011) which mentions only 
pregabalin and tiagabine as agents that have been investigated to a reasonable extent in 
GAD. The review also remarks on the good evidence base regarding the use of pregabalin in 
GAD, that the findings in tiagabine studies were generally unfavourable, and that there is 
little data on the other anticonvulsants in GAD. There was no meta-analysis or quantitative 
data presented by Mula (2011). The same conclusions were reached in an earlier review by 
Mula (2007).  
 
 Kinrys (2005) describe similar findings in their review concluding that there appears to be 
good early data from RCT’s demonstrating efficacy of pregabalin and that there are poorer 
quality studies of tiagabine with inconsistent results. The review also mentions two case 
reports of gabapentin and one of levetiracetam that showed potential in treating GAD but no 




The two reviews of anticonvulsant use in GAD by Van Ameringen (2008; Van Ameringen, 
Mancini, Pipe, et al., 2004a) are also consistent with the results of this dissertation. The 
findings note that pregabalin is already showing good evidence, tiagabine is showing mixed 
results but justifying further investigation and minimal evidence in the form of case reports 
for gabapentin and levetiracetam exists. There was no meta-analytic data in either review by 
Van Ameringen (2008; Van Ameringen, Mancini, Pipe, et al., 2004a). Huh (2011) published 
a review on alternatives to antidepressants in treating GAD and pregabalin was the only 
anticonvulsant that was recommended. This finding also supports the results of this 
dissertation.  
 
 Pregabalin, particularly, and its role in GAD has been quite comprehensively reviewed over 
the past few years. Most recently Baldwin (2015) published an extensive review of the 
existing literature regarding the efficacy and safety of pregabalin GAD. In his review, which 
is not a meta-analysis with any quantitative data, Baldwin (2015) examined the findings 
from 11 randomised double-blind trials and two open-label studies. The conclusions of 
Baldwin (2015) are largely consistent with the results of the systematic review conducted in 
this dissertation. Baldwin (2015) notes that pregabalin has consistently demonstrated to be 
an effective treatment in GAD, with a relatively benign side effect profile that is well-
tolerated by patients and it has a unique mechanism of action in comparison to other 
medications used in GAD which makes it a valuable treatment option. In contrast to this 
dissertation, Baldwin (2015) does not note that the bulk of the high quality RCT data on 
pregabalin comes from studies funded by the manufacturer 
 
Boschen (2011) performed a meta-analysis of pregabalin in the treatment of GAD in which 
seven published placebo controlled trials were considered. It is not straightforward to 
compare the results of Boschen (2011) to the results obtained in the meta-analysis of this 
dissertation due to differences in methodology. This dissertation used: a mean difference 
(MD) in HAM-A total score points as an effect estimate of symptom reduction; a random 
effects statistical model; a different mechanism of dealing with unit-of-analysis issues and 
provided dichotomous outcome data for calculating treatment response. In contrast, the 
meta-analysis by Boschen (2011): used Hedges’ g to calculate an overall effect size; used a 
fixed effects statistical model; utilised only the highest dosage of pregabalin in each trial as a 
method to overcome unit-of-analysis errors and did not provide a dichotomous outcome of 
treatment response.  
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The effect size using Hedges’ g is equivalent to the standardised mean difference (SMD) 
which is the term preferred by the Cochrane Collaboration (Higgins & Green, 2011). 
Boschen (2011) determined the overall effect size of pregabalin using Hedges’ g to be 0.364 
([0.256 to 0.551] (95% CI) P <0.001, Z= 6.06). The basic rules of thumb for interpreting 
SMD’s suggested by the Cochrane Collaboration includes: 0.2 = a small effect, 0.5 a 
moderate effect and 0.8 a large effect (Cohen, 1988); an alternative interpretation suggested 
is: < 0.40 = small, 0.40 to 0.70 = moderate, > 0.70 = large (Higgins & Green, 2011). Based 
on these rules of thumb, the SMD of 0.364 ([0.256 to 0.551] (95% CI)) reported by Boschen 
(2011) could be considered to represent a significant small to moderate effect of pregabalin 
in treating GAD. The MD in HAM-A points, obtained in this dissertation’s meta-analysis for 
pregabalin was -2.86 [-3.52, -2.21] (95% CI) and was statistically significant. These results 
both indicate a significant effect of pregabalin in treating GAD. However, the 
methodological differences between the two meta-analyses are probably too large to allow 
any firm conclusions to be drawn from their direct comparison. 
 
Limitations of This Study 
 
Among the many limitations of this study, the following were thought to be important. 
Although this systematic review is considered up-to-date as of May 2016, the last official 
search performed by the CCDANCTR was in August 2013. An updated, independent search 
of PubMed was conducted on the 16th of May 2016. It could be considered a limitation that 
an updated official search could not be performed by the CCDANCTR. Their resources 
could have allowed for a potentially more powerful and thorough search process. 
 
It could be considered a limitation that a multiple-treatment meta-analysis was not 
performed to deal with unit-of-analysis errors. The method used in this dissertation, although 
currently recommended by the Cochrane Collaboration (Higgins & Green, 2011), 
potentially could produce less accurate results than a multiple-treatment meta-analysis. 
 
 This review did not take into account the possibility of a dose-response relationship of an 
anticonvulsant due to the methodology employed. There appears to be conflicting evidence 
over whether pregabalin has a dose-response effect in GAD treatment (Boschen, 2012; 
Baldwin, Boer, Lyndon, et al., 2015). Despite this, not accounting for dose-response 
relationships might still be considered a limiting factor.  
74 
The various definitions of intention-to-treat (ITT) employed in the different trials has lead to 
the notion, as described above, of a modified-intention-to-treat (MIIT) sample number 
provided by each trial. The inconsistency in what constitutes a MIIT sample has been noted 
already by other researchers, as it could lead to inaccurate or misleading results (Hoskins, 
Pearce, Bethell, et al., 2015). This review used the MIIT provided by each relevant study, as 
on many occasions, each trial only had outcome data based on this MIIT. The results of the 
review should be interpreted with this in mind as potential limitation. 
 The scope of the conclusions of this dissertation could potentially be limited for the 
following reasons: only short-term RCT’s were evaluated and data from relapse prevention 
trials were omitted; consideration was only given to trials where a single anticonvulsant was 
compared to placebo; data from comparisons with active comparators was omitted and trials 
using anticonvulsants as adjunctive treatment in GAD were not considered. Conclusions 
could be further limited as outcome data from the RCTs was frequently in the incorrect 
format, only partially presented or, in some instances, missing completely. In the majority of 
cases it was possible to impute missing, or incomplete data using the statistical software 
within RevMan (Cochrane Collaboration, 2011). However, imputing data is not ideal as 
there is a potential risk that errors can be made during imputation which could lead to 
inaccurate results. In the case of Ionescu 2010 it was not possible to obtain any data to 
calculate treatment response and the trial had to be entirely omitted from the meta-analysis 
of treatment response. This will have certainly impacted the pooled effect estimate of 
treatment response in this meta-analysis. However, it is difficult to be certain as to size and 
manner of the effect this would have had on the overall estimate. 
The RCT’s included in this systematic review were all conducted in the United States and 
Europe. Also, almost all the trials had fairly strict exclusion criteria, especially regarding 
other psychiatric comorbidities and use of other psychotropic medications. Therefore, this 
can raise questions over the generalisabilty of these results. This would affect not only the 
generalisabilty to psychiatric practice overall, where comorbidity and polypharmacy in 
patients is the norm, but also in particular to low and middle income populations. 
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It must also be borne in mind that eleven of the twelve RCTs were funded by the company 
that manufactured the medication used as the intervention in the study. Although there were 
only a few occasions in the review process when it was necessary, attempts to obtain 
unpublished trial data from pharmaceutical companies were unsuccessful. Any missing 
unpublished data is a limiting factor and potentially could affect the results of a systematic 
review significantly. 
Conclusion 
In conclusion, pregabalin and tiagabine were the only agents, among the multiple newer 
anticonvulsants considered, that were found to be appropriate for inclusion in this systematic 
review and meta-analysis of GAD. The results demonstrated significant efficacy of 
pregabalin in symptom severity reduction and treatment response in GAD. Tiagabine, 
however, failed to show significant efficacy in the primary outcomes and displayed 
significantly unfavourable treatment acceptability.  
Implications for Clinical Practice 
 Pregabalin proved to be significantly efficacious in treating GAD with a reasonably good 
level of treatment acceptability. The dosages used ranged from 150mg/day up to 600mg/day 
within the different pregabalin trials. However, due to methodological limitations, it is not 
possible based on this review, to make a recommendation on the optimal dosage of 
pregabalin to use to achieve a clinical response. Similarly, because only short term studies of 
pregabalin were considered, ranging from 4 weeks to 8 weeks, recommendations cannot  be 
made on outcome variables beyond this duration including how long treatment should 
continue. Apart from pregabalin, there is no evidence from this systematic review to suggest 
that any of the other newer anticonvulsants considered, display efficacy in GAD over the 
time periods considered and the dosages used.  
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Implications for Future Research 
This review suggests that further work is needed to clarify the place of the newer 
anticonvulsants in the treatment armamentarium of GAD. In particular, it would be useful 
for further work to establish consensus on the position pregabalin should occupy in 
recognised treatment guidelines for GAD. It would useful in further work to determine the 
optimal dosage and duration of treatment that should be recommended in the use of 
pregabalin in treating GAD. 
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Appendices 
Table 4. The Data Tables 
1 Anticonvulsants Compared to Placebo in Treating GAD 
Outcome or 
Subgroup 







Total Score in 
The 
Anticonvulsan
t Compared to 
Placebo Group 
10 3986 Mean Difference 
(IV, Random, 95% 
CI) 
-2.10 [-2.83, -1.36]
  1.1.1 Feltner 
2003 
1 196 Mean Difference 
(IV, Random, 95% 
CI) 
-2.69 [-4.73, -0.65]
  1.1.2 Pande 
2003 
1 200 Mean Difference 
(IV, Random, 95% 
CI) 
-2.92 [-4.83, -1.02]
  1.1.3 Pohl 
2005 
1 341 Mean Difference 
(IV, Random, 95% 
CI) 
-3.28 [-5.09, -1.47]
  1.1.4 Rickels 
2005 
1 346 Mean Difference 
(IV, Random, 95% 
CI) 
-3.27 [-5.08, -1.46]
  1.1.5 Pollack 
2005 
1 260 Mean Difference 




  1.1.6 
Montgomery 
2006 
1 298 Mean Difference 
(IV, Random, 95% 
CI) 
-2.78 [-4.70, -0.86]
  1.1.8 
Montgomery 
2008 
1 266 Mean Difference 
(IV, Random, 95% 
CI) 
-2.10 [-4.33, 0.13]
  1.1.9 Pollack 
2008a 
1 840 Mean Difference 
(IV, Random, 95% 
CI) 
-0.07 [-1.33, 1.19]
  1.1.10 
Pollack 2008b 
1 441 Mean Difference 
(IV, Random, 95% 
CI) 
-0.30 [-1.99, 1.39]
  1.1.11 
Pollack 2008c 
1 438 Mean Difference 
(IV, Random, 95% 
CI) 
-1.40 [-3.07, 0.27]
  1.1.12 
Kasper 2009 
1 249 Mean Difference 
(IV, Random, 95% 
CI) 
-2.80 [-5.29, -0.31]
  1.1.13 
Ionescu 2010 
1 111 Mean Difference 











ts compared to 
Placebo 
10 4000 Risk Ratio (M-H, 
Random, 95% CI) 
1.23 [1.12, 1.35] 
  1.2.1 Feltner 
2003 
1 203 Risk Ratio (M-H, 
Random, 95% CI) 











1 200 Risk Ratio (M-H, 
Random, 95% CI) 
1.33 [0.85, 2.09] 






1 341 Risk Ratio (M-H, 
Random, 95% CI) 
1.69 [1.23, 2.31] 






1 346 Risk Ratio (M-H, 
Random, 95% CI) 
1.69 [1.20, 2.38] 




1 260 Risk Ratio (M-H, 
Random, 95% CI) 
1.20 [0.92, 1.57] 






1 298 Risk Ratio (M-H, 
Random, 95% CI) 
1.37 [1.06, 1.78] 
  1.2.7 
Montgomery 
2008 
1 273 Risk Ratio (M-H, 
Random, 95% CI) 










1 840 Risk Ratio (M-H, 
Random, 95% CI) 
1.08 [0.90, 1.29] 




1 441 Risk Ratio (M-H, 
Random, 95% CI) 
1.13 [0.91, 1.42] 




1 438 Risk Ratio (M-H, 
Random, 95% CI) 
1.00 [0.80, 1.26] 





1 249 Risk Ratio (M-H, 
Random, 95% CI) 
1.27 [1.00, 1.62] 





1 111 Risk Ratio (M-H, 
Random, 95% CI) 
Not estimable 
2 Pregabalin Compared to Placebo in Treating GAD 
Outcome or 
Subgroup 











  2.1.1 Feltner 
2003 




  2.1.2 Pande 
2003 




  2.1.3 Pohl 
2005 




  2.1.4 Rickels 
2005 




  2.1.6 
Montgomery 
2006 




  2.1.8 
Montgomery 
2008 




  2.1.12 
Kasper 2009 




  2.1.13 
Ionescu 2010 







8 2021 Risk Ratio (M-H, 
Random, 95% CI) 









1 203 Risk Ratio (M-H, 
Random, 95% CI) 
1.11 [0.79, 1.55] 






1 200 Risk Ratio (M-H, 
Random, 95% CI) 
1.33 [0.85, 2.09] 






1 341 Risk Ratio (M-H, 
Random, 95% CI) 
1.69 [1.23, 2.31] 






1 346 Risk Ratio (M-H, 
Random, 95% CI) 
1.69 [1.20, 2.38] 






1 298 Risk Ratio (M-H, 
Random, 95% CI) 
1.37 [1.06, 1.78] 
  2.2.7 
Montgomery 
2008 
1 273 Risk Ratio (M-H, 
Random, 95% CI) 










1 249 Risk Ratio (M-H, 
Random, 95% CI) 
1.27 [1.00, 1.62] 





1 111 Risk Ratio (M-H, 
Random, 95% CI) 
Not estimable 
3 Tiagabine Compared to Placebo in Treating GAD 
Outcome or 
Subgroup 










  3.1.5 
Pollack 2005 




  3.1.9 
Pollack 
2008a 




  3.1.10 
Pollack 
2008b 





  3.1.11 
Pollack 
2008c 
1 438 Mean Difference 
(IV, Random, 
95% CI) 






2 1979 Risk Ratio (M-H, 
Random, 95% CI) 
1.09 [0.98, 1.22] 




1 260 Risk Ratio (M-H, 
Random, 95% CI) 
1.20 [0.92, 1.57] 






1 840 Risk Ratio (M-H, 
Random, 95% CI) 
1.08 [0.90, 1.29] 





1 441 Risk Ratio (M-H, 
Random, 95% CI) 
1.13 [0.91, 1.42] 





1 438 Risk Ratio (M-H, 
Random, 95% CI) 
1.00 [0.80, 1.26] 
  














10 4110 Risk Ratio (M-
H, Random, 
95% CI) 
1.49 [1.18, 1.88] 




1 203 Risk Ratio (M-
H, Random, 
95% CI) 
2.22 [0.78, 6.29] 
  4.1.2 Pande 
2003 Pregabalin 
50mg TDS and 
200mg TDS 
1 208 Risk Ratio (M-
H, Random, 
95% CI) 
1.13 [0.49, 2.63] 





1 341 Risk Ratio (M-
H, Random, 
95% CI) 
1.35 [0.61, 2.98] 





1 361 Risk Ratio (M-
H, Random, 
95% CI) 
0.82 [0.39, 1.72] 
  4.1.5 Pollack 
2005 Tiagabine 
(2-16mg/day) 
1 266 Risk Ratio (M-
H, Random, 
95% CI) 
5.42 [1.22, 23.98] 





1 308 Risk Ratio (M-
H, Random, 
95% CI) 
1.02 [0.50, 2.09] 
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1 273 Risk Ratio (M-
H, Random, 
95% CI) 
1.15 [0.54, 2.43] 




1 884 Risk Ratio (M-
H, Random, 
95% CI) 
1.40 [0.90, 2.17] 
  4.1.9 Pollack 
2008b Tiagabine 
(4-16mg/day) 
1 456 Risk Ratio (M-
H, Random, 
95% CI) 
1.87 [1.10, 3.18] 
  4.1.10 Pollack 
2008c Tiagabine 
(4-16mg/day) 
1 450 Risk Ratio (M-
H, Random, 
95% CI) 
2.74 [1.30, 5.76] 




1 249 Risk Ratio (M-
H, Random, 
95% CI) 
2.27 [0.96, 5.37] 




1 111 Risk Ratio (M-
H, Random, 
95% CI) 
0.98 [0.30, 3.20] 
  













8 2054 Risk Ratio (M-
H, Random, 
95% CI) 
1.23 [0.92, 1.65] 
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1 203 Risk Ratio (M-
H, Random, 
95% CI) 
2.22 [0.78, 6.29] 
  5.1.2 Pande 
2003 Pregabalin 
50mg TDS and 
200mg TDS 
1 208 Risk Ratio (M-
H, Random, 
95% CI) 
1.13 [0.49, 2.63] 





1 341 Risk Ratio (M-
H, Random, 
95% CI) 
1.35 [0.61, 2.98] 





1 361 Risk Ratio (M-
H, Random, 
95% CI) 
0.82 [0.39, 1.72] 





1 308 Risk Ratio (M-
H, Random, 
95% CI) 
1.02 [0.50, 2.09] 





1 273 Risk Ratio (M-
H, Random, 
95% CI) 
1.15 [0.54, 2.43] 




1 249 Risk Ratio (M-
H, Random, 
95% CI) 
2.27 [0.96, 5.37] 
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1 111 Risk Ratio (M-
H, Random, 
95% CI) 
0.98 [0.30, 3.20] 













2 2056 Risk Ratio (M-
H, Random, 
95% CI) 
1.95 [1.29, 2.93] 
  6.1.5 Pollack 
2005 Tiagabine 
(2-16mg/day) 
1 266 Risk Ratio (M-
H, Random, 
95% CI) 
5.42 [1.22, 23.98] 




1 884 Risk Ratio (M-
H, Random, 
95% CI) 
1.40 [0.90, 2.17] 




1 456 Risk Ratio (M-
H, Random, 
95% CI) 
1.87 [1.10, 3.18] 
  6.1.10 Pollack 
2008c Tiagabine 
(4-16mg/day) 
1 450 Risk Ratio (M-
H, Random, 
95% CI) 
2.74 [1.30, 5.76] 
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